Tirzepatide represents a groundbreaking therapeutic agent for individuals facing type 2 diabetes. As a dual receptor activator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic https://adrianapmdm314961.pages10.com/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist-75948506